The detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML) can present a challenge because it can require detecting just several malignant cells within thousands – if not millions – of normal cells. One of the major challenges associated with the development and validation of assays for MRD in AML is the absence of cell-based reference materials that feature diverse mutations that may be encountered clinically.
In this scientific poster, SeraCare's scientific experts begin to address the need for standards by developing a full process cell-based reference materials.
To download, fill out the form and you will receive an email with the content.
